ATE463578T1 - Zusammensetzungen und verfahren zur auslösung einer immunantwort auf basis alphavirus-vektoren- systeme - Google Patents

Zusammensetzungen und verfahren zur auslösung einer immunantwort auf basis alphavirus-vektoren- systeme

Info

Publication number
ATE463578T1
ATE463578T1 AT00923558T AT00923558T ATE463578T1 AT E463578 T1 ATE463578 T1 AT E463578T1 AT 00923558 T AT00923558 T AT 00923558T AT 00923558 T AT00923558 T AT 00923558T AT E463578 T1 ATE463578 T1 AT E463578T1
Authority
AT
Austria
Prior art keywords
methods
triggering
compositions
vector systems
immune response
Prior art date
Application number
AT00923558T
Other languages
English (en)
Inventor
John Polo
Thomas Dubensky
Ilya Frolov
Jason Gardner
Gillis Otten
Susan Barnett
David Driver
Original Assignee
Novartis Vaccines & Diagnostic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Vaccines & Diagnostic filed Critical Novartis Vaccines & Diagnostic
Application granted granted Critical
Publication of ATE463578T1 publication Critical patent/ATE463578T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36141—Use of virus, viral particle or viral elements as a vector
    • C12N2770/36143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • AIDS & HIV (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT00923558T 1999-04-14 2000-04-14 Zusammensetzungen und verfahren zur auslösung einer immunantwort auf basis alphavirus-vektoren- systeme ATE463578T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US12949899P 1999-04-14 1999-04-14
US14808699P 1999-08-09 1999-08-09
US19136300P 2000-03-22 2000-03-22
PCT/US2000/010722 WO2000061772A2 (en) 1999-04-14 2000-04-14 Compositions and methods for generating an immune response utilizing alphavirus-based vector systems

Publications (1)

Publication Number Publication Date
ATE463578T1 true ATE463578T1 (de) 2010-04-15

Family

ID=27383889

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00923558T ATE463578T1 (de) 1999-04-14 2000-04-14 Zusammensetzungen und verfahren zur auslösung einer immunantwort auf basis alphavirus-vektoren- systeme

Country Status (9)

Country Link
US (1) US7771979B2 (de)
EP (2) EP1175497B1 (de)
JP (1) JP4637368B2 (de)
AT (1) ATE463578T1 (de)
AU (1) AU4366000A (de)
CA (2) CA2373300C (de)
DE (1) DE60044125D1 (de)
DK (1) DK1175497T3 (de)
WO (1) WO2000061772A2 (de)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2434546C (en) 2001-01-12 2012-09-11 Chiron Corporation Induction of immune response by a replication-defective venezuelan equine encephalitis-sindbis chimeric virus replicon particle encoding an antigen
ES2624854T3 (es) 2001-05-31 2017-07-17 Glaxosmithkline Biologicals Sa Partículas de replicón de alfavirus quimérico
ES2330202T5 (es) 2001-09-06 2014-01-20 Alphavax, Inc. Sistemas vectores basados en replicones de alfavirus
AU2003287557A1 (en) * 2002-11-07 2004-06-03 Lung-Ji Chang Modified dendritic cells
CA2509973C (en) 2002-12-13 2013-02-26 Alphavax, Inc. Multi-antigenic alphavirus replicon particles and methods
DK3246399T3 (da) 2002-12-13 2021-10-04 Alphavax Inc Alfavirus-partikler og fremgangsmåder til fremstilling
MXPA05010007A (es) 2003-03-20 2006-03-10 Alphavax Inc Replicones de alfavirus y construcciones auxiliares mejorados.
PT1651666E (pt) 2003-07-11 2009-08-28 Alphavax Inc Vacinas de citomegalovírus à base de alfavírus
US8828957B2 (en) * 2003-12-11 2014-09-09 Microvax, Llc Methods for generating immunity to antigen
MXPA06013124A (es) 2004-05-18 2007-05-23 Alphavax Inc Vectores de alfavirus derivados de tc-83, particulas y metodos.
US20090104226A1 (en) 2004-05-21 2009-04-23 Novartis Vaccines And Diagnostics Inc. Alphavirus Vectors for Respiratory Pathogen Vaccines
WO2006130855A2 (en) 2005-06-01 2006-12-07 California Institute Of Technology Method of targeted gene delivery using viral vectors
WO2007047749A1 (en) 2005-10-18 2007-04-26 Novartis Vaccines And Diagnostics Inc. Mucosal and systemic immunizations with alphavirus replicon particles
CA2630220C (en) 2005-11-22 2020-10-13 Doris Coit Norovirus and sapovirus antigens
PL2048955T3 (pl) 2006-07-21 2013-11-29 California Inst Of Techn Nakierowane dostarczanie genu dla szczepienia komórek dendrytycznych
WO2008156829A2 (en) 2007-06-21 2008-12-24 Alphavax, Inc. Promoterless cassettes for expression of alphavirus structural proteins
JP5543921B2 (ja) 2007-10-15 2014-07-09 コリドン ピーティーワイ リミテッド 免疫応答をモジュレートするための発現系
SG177744A1 (en) 2009-07-24 2012-02-28 Immune Design Corp Lentiviral vectors pseudotyped with a sindbis virus envelope glycoprotein
US9795658B2 (en) 2010-04-20 2017-10-24 Admedus Vaccines Pty Ltd Expression system for modulating an immune response
US9422529B2 (en) * 2010-12-22 2016-08-23 The Board Of Regents Of The University Of Texas System Alphavirus compositions and methods of use
WO2012088473A1 (en) * 2010-12-22 2012-06-28 The Board Of Regents Of The University Of Texas System Alphavirus compositions and methods of use
WO2012106356A2 (en) 2011-01-31 2012-08-09 GOVERNMENT OF THE USA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH & HUMAN SERVICES Virus-like particles and methods of use
ES2861428T3 (es) 2011-07-06 2021-10-06 Glaxosmithkline Biologicals Sa Liposomas que presentan una relación N:P útil para suministro de moléculas de ARN
US8323662B1 (en) 2012-03-30 2012-12-04 Immune Design Corp. Methods useful for generating highly mannosylated pseudotyped lentiviral vector particles comprising a Vpx protein
US9713635B2 (en) 2012-03-30 2017-07-25 Immune Design Corp. Materials and methods for producing improved lentiviral vector particles
NZ700340A (en) 2012-03-30 2017-02-24 Immune Design Corp Lentiviral vector particles having improved transduction efficiency for cells expressing dc- sign
US20150140068A1 (en) * 2012-07-06 2015-05-21 Novartis Ag Immunogenic compositions and uses thereof
ES2752190T3 (es) 2012-09-14 2020-04-03 Us Health Proteína Brachyury, vectores adenovirales que codifican proteína Brachyury y su uso
US9481714B2 (en) * 2012-12-05 2016-11-01 Thevax Genetics Vaccine Co., Ltd. Fusion proteins for use as immunogenic enhancers for inducing antigen-specific T cell responses
CA2930693A1 (en) 2013-11-15 2015-05-21 The Board Of Trustees Of The Leland Stanford Junior Unversity Methods of treating heart failure with agonists of hypocretin receptor 2
WO2017004022A2 (en) 2015-06-29 2017-01-05 The Board Of Trustees Of The Leland Stanford Junior University Degron fusion constructs and methods for controlling protein production
KR20250107975A (ko) 2015-08-03 2025-07-14 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 브라큐리 결실 돌연변이체, 브라큐리 결실 돌연변이체를 인코딩하는 비-효모 벡터, 및 이들의 용도
CN108601951B (zh) 2015-12-09 2022-11-22 金港医疗(澳大利亚)私人有限公司 用于治疗的免疫调节组合物
CN108778365B (zh) 2016-01-11 2021-05-25 沃达瑞公司 微针组合物及其使用方法
CA3028682A1 (en) 2016-06-20 2017-12-28 Howard Y. Chang Circular rnas and their use in immunomodulation
BR112019023477A2 (pt) 2017-05-08 2020-06-30 Gritstone Oncology, Inc. vetores de neoantígeno de alfavírus
EP3682004A4 (de) 2017-09-15 2021-05-26 The Board of Trustees of the Leland Stanford Junior University Multiplex-herstellung und barcodierung von genetisch veränderten zellen
MX2020007077A (es) 2018-01-04 2020-10-28 Iconic Therapeutics Inc Anticuerpos anti-factor tisular, conjugados anticuerpo-farmaco y metodos relacionados.
NL2022538B1 (en) 2019-02-08 2020-08-19 Academisch Ziekenhuis Groningen Methods for providing purified viral particles of Semliki Forest Virus (SFV), preparations obtainable thereby, and uses thereof.
WO2020243719A1 (en) 2019-05-30 2020-12-03 Gritstone Oncology, Inc. Modified adenoviruses
IL294290A (en) 2019-12-31 2022-08-01 Elixirgen Therapeutics Inc Transient temperature-based delivery of nucleic acids and proteins to cells and tissues
IL300026A (en) 2020-08-06 2023-03-01 Gritstone Bio Inc Multiepitope vaccine cassettes
EP4419684A1 (de) 2021-10-21 2024-08-28 The J. David Gladstone Institutes, A Testamentary Trust Established under The Will of J. David Gladstone Retroelementerzeugte transkriptionsfaktorköder
US20250043269A1 (en) 2021-11-03 2025-02-06 The J. David Gladstone Institutes, a testamentary trust established under the Will of J. David Glad Precise Genome Editing Using Retrons
WO2023141602A2 (en) 2022-01-21 2023-07-27 Renagade Therapeutics Management Inc. Engineered retrons and methods of use
CA3246348A1 (en) 2022-03-25 2023-09-28 The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone RT-DNA AND RETRONS FIDELITY GENOMIC EDITING
US20250223586A1 (en) 2022-03-25 2025-07-10 The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Methods of assessing engineered retron activity, and uses thereof
US20250215458A1 (en) 2022-03-25 2025-07-03 The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Production of reverse transcribed DNA (RT-DNA) using a retron reverse transcriptase from exogenous RNA
EP4558624A2 (de) 2022-07-18 2025-05-28 Renagade Therapeutics Management Inc. Geneditierkomponenten, systeme und verfahren zur verwendung
WO2024044673A1 (en) 2022-08-24 2024-02-29 The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone Dual cut retron editors for genomic insertions and deletions
WO2024044723A1 (en) 2022-08-25 2024-02-29 Renagade Therapeutics Management Inc. Engineered retrons and methods of use
WO2025081042A1 (en) 2023-10-12 2025-04-17 Renagade Therapeutics Management Inc. Nickase-retron template-based precision editing system and methods of use
WO2025155753A2 (en) 2024-01-17 2025-07-24 Renagade Therapeutics Management Inc. Improved gene editing system, guides, and methods

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5171568A (en) 1984-04-06 1992-12-15 Chiron Corporation Recombinant herpes simplex gb-gd vaccine
CA1341423C (en) 1984-10-31 2003-03-04 Paul A. Luciw Recombinant proteins of viruses associated with lymphadenopathy syndrome and/or acquired immune deficiency syndrome
US5466788A (en) * 1985-03-07 1995-11-14 Mycogen Plant Science, Inc. Subgenomic promoter
JP2528107B2 (ja) 1985-03-15 1996-08-28 サマ−トン，ジエ−ムス ポリヌクレオチド測定試薬と方法
US5185444A (en) 1985-03-15 1993-02-09 Anti-Gene Deveopment Group Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages
US5091309A (en) 1986-01-16 1992-02-25 Washington University Sindbis virus vectors
US4927750A (en) 1986-04-09 1990-05-22 Jeanette Simpson Cell separation process
CA1338800C (en) 1986-06-17 1996-12-17 Michael Houghton Hepatitis delta and diagnostics and vaccines
US5716826A (en) * 1988-03-21 1998-02-10 Chiron Viagene, Inc. Recombinant retroviruses
US5217879A (en) 1989-01-12 1993-06-08 Washington University Infectious Sindbis virus vectors
US5026686A (en) * 1989-02-01 1991-06-25 Washington University Antiviral peptides
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
JPH0832638B2 (ja) 1989-05-25 1996-03-29 カイロン コーポレイション サブミクロン油滴乳剤を含んで成るアジュバント製剤
US5185440A (en) * 1989-06-20 1993-02-09 North Carolina State University cDNA clone coding for Venezuelan equine encephalitis virus and attenuating mutations thereof
SE9003978D0 (sv) 1990-12-13 1990-12-13 Henrik Garoff Dna expressionssystem baserade paa ett virus replikon
JP3649335B2 (ja) 1992-04-01 2005-05-18 ザ ロックフェラー ユニバーシティー 樹枝状細胞前駆体のインビトロ増殖の方法およびその免疫原製造への使用
WO1994017813A1 (en) 1993-02-08 1994-08-18 Paravax, Inc. Defective sindbis virus vectors that express toxoplasma gondii p30 antigens
US5578475A (en) * 1993-07-12 1996-11-26 Life Technologies, Inc. Composition and methods for transfecting eukaryotic cells
US6015686A (en) 1993-09-15 2000-01-18 Chiron Viagene, Inc. Eukaryotic layered vector initiation systems
US5591579A (en) * 1993-12-21 1997-01-07 Washington University Indicator cell line for detecting RNA viruses and method therefor
US5532154A (en) * 1994-03-21 1996-07-02 Research Development Foundation Mutated alpha virus
DE4412794A1 (de) 1994-04-14 1995-12-14 Univ Ludwigs Albert Verfahren zur Herstellung von dendritischen Zellen, so erhaltene Zellen und Behälter zur Durchführung dieses Verfahrens
US5505947A (en) * 1994-05-27 1996-04-09 The University Of North Carolina At Chapel Hill Attenuating mutations in Venezuelan Equine Encephalitis virus
US5663051A (en) 1994-08-31 1997-09-02 Activated Cell Therapy, Inc. Separation apparatus and method
US5646004A (en) 1994-08-31 1997-07-08 Activated Cell Therapy, Inc. Methods for enriching fetal cells from maternal body fluids
US5648219A (en) 1995-06-07 1997-07-15 Zymogenetics, Inc. Immortalized dendritic cells
JPH11504802A (ja) * 1994-11-30 1999-05-11 カイロン コーポレイション 組換えアルファウイルスベクター
US5648248A (en) 1994-12-30 1997-07-15 Boehringer Ingelheim International Gmbh Methods for producing differentiated cells from immature hematopoietic cells
US5643786A (en) 1995-01-27 1997-07-01 The United States Of America As Represented By The Department Of Health And Human Services Method for isolating dendritic cells
US5871728A (en) 1995-03-31 1999-02-16 University Of Pittsburgh Method of regulating dendritic cell maturation
US5792462A (en) 1995-05-23 1998-08-11 University Of North Carolina At Chapel Hill Alphavirus RNA replicon systems
US5797870A (en) * 1995-06-07 1998-08-25 Indiana University Foundation Pericardial delivery of therapeutic and diagnostic agents
US5788963A (en) 1995-07-31 1998-08-04 Pacific Northwest Cancer Foundation Isolation and/or preservation of dendritic cells for prostate cancer immunotherapy
US5811297A (en) 1996-03-07 1998-09-22 Amba Biosciences, Llc Immortalized hematopoietic cell lines, cell system thereof with stromal cells, in vitro, ex vivo and in vivo uses, & in vitro generation of dendritic cells and macrophages
WO1997038087A2 (en) * 1996-04-05 1997-10-16 Chiron Corporation Alphaviral vector with reduced inhibition of cellular macromolecular synthesis
US5843712A (en) * 1996-06-06 1998-12-01 The Trustees Of Columbia University In The City Of New York Sindbis virus expression system for recombinant antibody production
US5842723A (en) 1996-11-25 1998-12-01 Burex Automotive America, Inc. Flexible connection arrangement for connecting a pipe of an exhaust system to an engine, especially in a motor vehicle
US5811407A (en) * 1997-02-19 1998-09-22 The University Of North Carolina At Chapel Hill System for the in vivo delivery and expression of heterologous genes in the bone marrow
JP2002510647A (ja) * 1998-04-08 2002-04-09 ユニバーシティ オブ ノース カロライナ アット チャペル ヒル 癌の治療のための方法および修飾細胞

Also Published As

Publication number Publication date
EP2196472A2 (de) 2010-06-16
CA2373300A1 (en) 2000-10-19
WO2000061772A2 (en) 2000-10-19
WO2000061772A3 (en) 2001-02-08
EP1175497A2 (de) 2002-01-30
CA2760534A1 (en) 2000-10-19
AU4366000A (en) 2000-11-14
EP2196472A3 (de) 2011-04-13
DK1175497T3 (da) 2010-05-31
US20080226598A1 (en) 2008-09-18
US7771979B2 (en) 2010-08-10
EP1175497B1 (de) 2010-04-07
JP2002541814A (ja) 2002-12-10
CA2373300C (en) 2012-02-21
DE60044125D1 (de) 2010-05-20
JP4637368B2 (ja) 2011-02-23

Similar Documents

Publication Publication Date Title
ATE463578T1 (de) Zusammensetzungen und verfahren zur auslösung einer immunantwort auf basis alphavirus-vektoren- systeme
AU2001249380A1 (en) Compositions and methods for generating an immune response utilizing alphavirus-based vector systems
DE60335010D1 (de) Immunstimulatorische zusammensetzungen und verfahren zur stimulierung einer immunantwort
DE69927956D1 (de) Shampoo zusammensetzungen auf basis von silikon
ES2182984T3 (es) Mejoras relativas a dispositivos de localizacion.
DE69821572D1 (de) Verfahren und Schaltkreis zur Diodenlaseransteuerung
IT1291233B1 (it) Procedimento per sterilizzare terreni e relativa attrezzatura.
DE69300024D1 (de) Vorrichtung zur Erzeugung von Bezugsspannungen.
DE60138527D1 (de) Kabelschutzfeder und verfahren zur befestigung der kabelschutzfeder
EP1483385A4 (de) Zusammensetzungen und verfahren zur erzeugung einer immunantwort
DE10085297T1 (de) Verfahren und Vorrichtung zur Erzeugung einer Bewegungsillusion
DE59002879D1 (de) Vorrichtung zur anbringung an stuhlbeinen od. dgl.
DE69827545D1 (de) Vorrichtung zur Erzeugung von Hintergrundrauschen
DE50011228D1 (de) Vorrichtung zur befestigung von schaltgeräten auf tragschienen
DE69910852D1 (de) Vorrichtung zur Erzeugung rauscharmer Stromstösse
ATA64196A (de) Vorrichtung zum auslösen einer lawine od.dgl.
DE50109056D1 (de) Schaltungsanordnung zur Ansteuerung einer Insassenschutzvorrichtung
DE59914381D1 (de) Vorrichtung zur Erzeugung von Geräuschen technischer Geräte
DE59102869D1 (de) Verfahren und vorrichtung zum erfassen und übertragen von informationen bei relativ zueinander verfahrbaren elektrischen leitern od. dgl.
IT1304662B1 (it) Procedimento e dispositivo di stampa su oggetti tridimensionali.
DE60116741D1 (de) Schaltung, verfahren und system zur erzeugung einer nichtlinearen transfercharakteristik
NL193701B (nl) Inrichting voor het opwekken van stoom.
NL1000270A1 (nl) Sorteerinrichting voor het sorteren van champignons, een samenstel van dergelijke sorteerinrichtingen, en werkwijze voor het sorteren van champignons.
NL1007118A1 (nl) -- Werkwijze voor het opwekken van een röntgenstralenmicrobundel en inrchting daarvoor.
MA25251A1 (fr) Equipement de protection d'installations avec modulation d'impulsions codifiees.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1175497

Country of ref document: EP